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CLINICAL SCIENCE
The Safety of Tenofovir–Emtricitabine for HIV Pre-Exposure
Prophylaxis (PrEP) in Individuals With Active Hepatitis B
Marc M. Solomon, MD, MPH,*† Mauro Schechter, MD, PhD,‡ Albert Y. Liu, MD, MPH,†§
Vanessa M. McManhan, MS,* Juan V. Guanira, MD, MPH,k Robert J. Hance, AA,*
Suwat Chariyalertsak, MD, DrPH,¶ Kenneth H. Mayer, MD,# and Robert M. Grant, MD, MPH,*† for the
iPrEx Study Team
Background: Pre-exposure prophylaxis (PrEP) with daily oral
emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) prevents
HIV infection. The safety and feasibility of HIV PrEP in the setting
of hepatitis B virus (HBV) infection were evaluated.
Methods: The Iniciativa Profilaxis Pre-Exposición study randomized
2499 HIV-negative men and transgender women who have sex with men
to once-daily oral FTC/TDF versus placebo. Hepatitis serologies and
transaminases were obtained at screening and at the time PrEP was
discontinued. HBV DNA was assessed by polymerase chain reaction,
and drug resistance was assessed by population sequencing. Vaccination
was offered to individuals susceptible to HBV infection.
Results: Of the 2499 participants, 12 (0.5%; including 6 random-
ized to FTC/TDF) had chronic HBV infection. After stopping FTC/
TDF, 5 of the 6 participants in the active arm had liver function tests
performed at follow-up. Liver function tests remained within normal
limits at post-stop visits except for a grade 1 elevation in 1 participant at
post-stop week 12 (alanine aminotransferase = 90, aspartate amino-
transferase = 61). There was no evidence of hepatic flares. Polymerase
chain reaction of stored samples showed that 2 participants in the active
arm had evidence of acute HBV infection at enrollment. Both had
evidence of grade 4 transaminase elevations with subsequent resolu-
tion. Overall, there was no evidence of TDF or FTC resistance among
tested genotypes. Of 1633 eligible for vaccination, 1587 (97.2%)
received at least 1 vaccine; 1383 (84.7%) completed the series.
Conclusions: PrEP can be safely provided to individuals with
HBV infection if there is no evidence of cirrhosis or substantial
transaminase elevation. HBV vaccination rates at screening were low
globally, despite recommendations for its use, yet uptake and
efficacy were high when offered.
Key Words: HIV, pre-exposure prophylaxis, hepatitis B, MSM,
PrEP safety, transgender women
(J Acquir Immune Defic Syndr 2016;71:281–286)
INTRODUCTION
Antiretroviral pre-exposure prophylaxis (PrEP) with
daily oral emtricitabine and tenofovir disoproxil fumarate
(FTC/TDF) prevents acquisition of HIV infection in adults1–4
and is recommended by the Centers for Disease Control and
Prevention (CDC) in the United States as part of a compre-
hensive package of preventative measures for individuals at
substantial risk of HIV acquisition.5 FTC/TDF PrEP has an
excellent safety profile and is well tolerated with subclinical
effects on renal function6 and bone mineral density.7,8
FTC/TDF is also active against hepatitis B; however,
concern has been raised that providing PrEP to individuals
infected with hepatitis B could lead to hepatitis flares and
injury, especially in the setting of suboptimal PrEP adherence
or PrEP discontinuation.9 This concern stems from data on
HIV-hepatitis B virus (HBV) coinfected individuals with
chronic hepatitis B infections and cirrhosis who have high
rates of hepatitis flares, sometimes leading to hepatic failure if
they discontinue treatment for HIV with agents that are dually
active against both HIV and HBV.10,11
The effect of PrEP use on hepatitis B infection is not well
understood and most PrEP trials excluded participants with
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circulating HBV surface antigen at baseline.2,12 There are no
reported cases of flares in HIV-uninfected persons with chronic
hepatitis B infection who have discontinued FTC/TDF PrEP,
although clinical experience with PrEP remains limited. Owing
to the complexity of hepatitis B management, the CDC PrEP
guidelines recommend that individuals positive for hepatitis B
surface antigen be referred to a clinician who specializes in the
treatment of hepatitis B before the initiation of PrEP.5
Furthermore, individuals susceptible to hepatitis B infec-
tion should be vaccinated,5 but recent data from the National
Health and Wellness Survey suggest that only 26.3% of adults
and 34.2% of men who have sex with men (MSM) in the US
have ever received a hepatitis B vaccine.13 Although sparse, data
on Latin American MSM cohorts also reveal low vaccination
rates: only 7% in a cohort in Argentina reported ever receiving
a hepatitis B vaccine.14 Even when HIV-infected individuals
were found to be susceptible for hepatitis B, only 25% were
vaccinated in a multicenter study of HIV-positive MSM in the
US.15 PrEP delivery could offer an additional opportunity to
evaluate hepatitis B serostatus and increase vaccination rates.
We sough to provide information about hepatitis B
global epidemiology, vaccine uptake and the safety of PrEP
use among hepatitis B-infected men who have sex with men
(MSM) and transgender women in the Iniciativa Profilaxis
Pre-Exposición (iPrEx) study.
METHODS
The iPrEx study randomized 2499 MSM to evaluate the
safety and efficacy of once-daily oral FTC/TDF PrEP for HIV
prevention.2 Study visits were scheduled every 4 weeks after
enrollment.2 A secondary end point of the iPrEx study was
the proportion of hepatic flares among subjects with active
hepatitis B infection.
Hepatitis B surface antibody (HBsAb), hepatitis B core
antibody (HBcAb), hepatitis B surface antigen (HBsAg), and
hepatitis C antibody were obtained at screening of all
participants. In addition, hepatitis serologies were repeated
at the time PrEP was stopped if HBV infection status was
ambiguous at baseline or if the study participants were
susceptible at baseline. Participants at screening who were
positive for HBcAb and negative for HBsAb were also tested
for HBcAb IgM (HBcAb IgM) to distinguish acute from
chronic infection. Individuals were excluded from the trial if
the HBcAb IgM was positive, if they had indications for HBV
treatment based on local practice standards, or had elevations
in liver function tests (LFTs), including alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), or total
bilirubin more than 2-fold the upper limit of normal (ULN)
within 28 days of enrollment, or signs of hepatic cirrhosis. All
participants with evidence of active hepatitis B infection were
excluded from participation at sites in Brazil because of local
concerns about safety and treatment monitoring requirements.
Hepatitis B e antigen (HBeAg) and hepatitis B e antibody
(HBeAb) were tested for in enrolled participants with a positive
HBsAg and when the activity of HBV remained ambiguous
after initial screening (ie, when HBcAb was positive, HBsAb
was negative, and HBcAb IgM was negative). Participants with
a positive HBsAg were followed up with a medical history and
LFTs at weeks 4, 8, 12, 16, 20, and 24 after stopping study
drugs to assess for flares. Participants were also tested for
elevated LFTs if they had signs or symptoms of hepatitis during
the study and when deemed clinically appropriate.
For enrolled individuals with a positive HBsAg at any
time during the trial, HBV DNA was measured via poly-
merase chain reaction. A HBV genotype was obtained for all
participants with measurable HBV DNA.
Narratives were constructed for participants who were
randomized to the FTC/TDF arm and were found to have
acute hepatitis B infection.
Participants found to be HBV susceptible at screening
were offered vaccination starting at their enrollment visit or at
any time thereafter during study participation. When war-
ranted by local medical practice standards, sites tested for
HBsAb after vaccination and could provide an additional
vaccine dose if HBsAb titers were insufficient. Flares were to
be managed by specialists in internal medicine at the study
site or referred to local specialists. Nucleoside and nucleotide
analogue reverse transcriptase inhibitors were available for
treatment of hepatitis B flares at study sites.
In a subset of participants, blood plasma was tested for
the presence of FTC and tenofovir (TFV), and peripheral
blood mononuclear cells were tested for FTC triphosphate
and TFV diphosphate.16
DEFINITIONS
Active hepatitis B was defined as either acute hepatitis
B or chronic hepatitis B infection.
Acute hepatitis B was defined by HBcAb, HBcAb IgM
and HBsAg positivity, and HBsAb negativity.
Chronic hepatitis B was defined by HBsAg and HBcAb
positivity with HBsAb and HBcAb IgM negativity. Other
hepatitis B designations are described in Table 1. A hepatic
flare was defined as an increase in AST or ALT to more than
5 times ULN at any visit or .2.5 times ULN for 3 months,
within 24 weeks of permanently discontinuing the study drug.
RESULTS
Screening
Four thousand nine hundred five individuals were
screened for iPrEx. Baseline hepatitis B serologies were
obtained from 4459 individuals (Table 2).
According to self-report, only 23.4% (1038/4431) had
ever received a hepatitis B vaccine of which less than half
45.7% (447/977) had received all 3 recommended vaccines.
Vaccination rates varied widely by site (range: 20.6%–90.7%),
with US and Brazilian sites reporting the highest rates (83%–
91%) and the Andean sites reporting the lowest (21%–27%).
Enrollment
Chronic HBV Cases
Among 2499 enrolled participants, 12 (0.48%) (6 cases
in each arm, mean age = 31 [range: 20–54] years) had chronic
HBV infection, all with positive HBsAg and HBcAb, and
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negative HBsAb and HBcAb IgM. Five were from the Andes
(4 from Peru and 1 from Ecuador), 4 from Thailand, 1 from
South Africa, and 2 from the US. All tested negative for
hepatitis C antibodies.
Chronic HBV Cases Randomized to FTC/TDF
Of the 6 HBsAg-positive cases in the active arm, 5 were
negative for HBeAg and positive for HBeAb, and 1 was
positive for HBeAg and negative for HBeAb (Figs. 1, 2A).
The HBV DNA at baseline ranged from 0 to 8849 copies per
milliliter in HBeAg-negative participants and was
336,000,000 copies per milliliter in the HBeAg-positive
participants at baseline. Of the 5 individuals with HBV
genotypes obtained, 3 had genotypes obtained after some
exposure to FTC/TDF PrEP, and none had evidence of
antiviral drug resistance. (One participant randomized to the
placebo arm had the 80P mutation with possible resistance to
lamivudine and telbivudine). After drug discontinuation, 5 of
6 participants had LFTs performed at one or more post-stop
follow-up visits (range: 6–7 visits). LFTs remained within
normal limits at all post-stop visits for 5 of 6 participants,
with no evidence of hepatic flares. In one participant
randomized to FTC/TDF, grade 1 LFT elevations were seen
at post-stop week 12 visit, with AST 61 (ULN 41) and ALT
90 (ULN 38); at the post-stop week 24 visit, AST was 37 and
ALT was 60. These elevations did not meet protocol criteria for
hepatic flares.17 Post-stop testing was not available in 1
participant who moved away. All 6 participants had evidence
of detected drug at one or more visits. One participant with
HBV viral load suppressed on FTC/TDF later developed
a HBV viral rebound to 24,703 copies at a time when no drug
was detected before permanent study drug discontinuation. The
transaminases from the same date were ALT = 44 and AST =
51. Overall, while on randomized treatment, HBV viral loads
ranged from 0 to 6205 at time points with detected drug and
0 to .3.41 · 109 at time points with no detected drug.
Narratives for 2 Acute HBV Cases
Randomized to Receive FTC/TDF
A 25-year-old man was randomized to FTC/TDF and
dispensed study drug at enrollment (Fig. 2B). This participant
was hepatitis B susceptible at screening (all negative for
HBsAg, HBcAb, and HBsAb) with normal LFTs. At week 4,
the participant had elevated LFTs (AST = 205, ALT = 669),
and serologies showed negative for HBsAg, HBsAb, HBeAg;
positive for HBcAb, HBcAb IgM, HBeAb at that visit. LFTs
normalized 2 weeks later, and by week 28, he developed
positive HBsAb and positive total HBcAb suggesting resolution
of infection with protective immunity. Enrollment specimens
were retrospectively tested and found to have an HBV viral
load of 30,684, no evidence of resistance, HBsAg positive,
HBcAb negative, HBsAb negative, and normal LFTs.
A 35-year-old participant was randomized to FTC/TDF
and dispensed study drug on the day of enrollment. At
screening, the participant had normal AST/ALT (35/35), with
serologies consistent with chronic HBV infection: positive for
HBsAg, HBcAb, and HBeAg and negative for HBsAb,
HBcAb IgM, and HBeAb. Testing at enrollment (15 days
after his screening visit) indicated that his AST/ALT had
increased to 214/304 (grade 3) before PrEP initiation. Eight
days after enrollment, repeat LFTs at an interim visit indicated
grade 4 elevations (ALT 1061, AST 1473), and PrEP was
TABLE 1. Interpretation of the Hepatitis B Panel at Baseline
Tests Results Interpretation and Management
HBsAg Negative Susceptible. Offer vaccination
series. If accepted, flag chart as
“HBV vaccine series”; if
vaccination is refused, then test
the entire panel when stopping
study drug and assign HBV flare
risk accordingly
anti-HBc Negative
anti-HBs Negative
HBsAg Negative Immune because of natural
infection. Flag chart as “HBV
Immune.” No further testing
anti-HBc Positive
anti-HBs Positive
HBsAg Negative Immune because of hepatitis B
vaccination. Flag chart as “HBV
Immune.” No further testing
anti-HBc Negative
anti-HBs Positive
HBsAg Positive Acutely infected, Flag chart as “At
Risk for HBV Flare.” Not
eligible for enrollment
anti-HBc Positive
anti-HBs Negative
anti-HBc IgM Positive
HBsAg Positive Chronically infected, Flag chart as
“At Risk for HBV Flare” Test for
HBeAg and anti-HBe at
enrollment
anti-HBc Positive
anti-HBs Negative
anti-HBc IgM Negative
HBsAg Negative Four interpretations possible: 1.
Might be recovering from acute
HBV infection; 2. Might be
distantly immune and anti-HBs
test is not sensitive enough to
detect low levels of anti-HBs; 3.
Might be susceptible with
a false-positive anti-HBc; 4.
Might be undetectable level of
HBsAg in the serum, and the
person is actually chronically
infected or undetectable HBsAg
because of the presence of
mutant HBV
anti-HBc Positive
anti-HBs Negative
HBsAg Other result patterns
not listed above
Possible assay error
anti-HBc
anti-HBs
TABLE 2. Hepatitis B Serologies Among Individuals Who
Screened for iPrEx
N (%)
Individuals screened for iPrEx 4459
Susceptible 2828 (63.4)
Immune because of natural infection 794 (17.8)
Immune because of hepatitis B vaccination 529 (11.9)
Infected with hepatitis B (acute and chronic) 61 (1.4)
Acutely infected 22 (0.5)
Chronically infected 39 (0.9)
Four interpretations possible 246 (5.5)
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stopped. At that time, there was evidence of an acute HBV
infection with interval appearance of detected HBcAb IgM and
continuing positive HBsAg, HBcAb, positive HBeAg, and
negative HBsAb and HBeAb. Eleven weeks later, his AST/
ALT returned to normal, and he was restarted on study drug 3
weeks later. Retrospective analysis at enrollment revealed
a HBV viral load .3.41 · 109 copies that was undetectable
by week 24 and remained undetectable for the duration of
participant’s time in the study. During visits at study weeks 28
and 72, HBV serology showed interval loss of HBsAg and
HBeAg and interval appearance of HBeAb, yet still no
detectable HBsAb. The patient self-terminated his participation
in the study early at week 80 citing time constraints.
Vaccine Uptake
Of the 2499 enrolled participants, 1633 (65.4%) were
eligible for hepatitis B immunization. One thousand five
hundred eighty-seven (97.2%) participants received at least
one hepatitis B immunization, and 1383 (84.7% of total eligible)
participants received the complete series of 3 injections.
Vaccine Response
Of the 1383 participants who received the complete
hepatitis B vaccination series with 3 doses and post-
vaccination serologic testing, 86.9% (1021/1175) developed
immunity as measured by a positive HBsAb. 44.4% (12/27)
and 74.5% (38/51) of the individuals who received 1 or 2
doses, respectively, developed immunity. Two individuals
who did not attain immunity were administered a fourth dose.
Neither individual developed subsequent immunity.
DISCUSSION
In this large multinational randomized placebo-
controlled clinical trial of oral FTC/TDF for HIV PrEP,
hepatitis B exposure was highly prevalent (.25% of
FIGURE 1. A-F, Hepatitis B virus and LFTs over time for the 6 participants with chronic hepatitis B randomized to FTC/TDF.
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participants screened with evidence of prior or active
infection). Although over 60% of the participants were
HBV susceptible at screening, fewer than 25% had reported
ever receiving an HBV vaccine. Among those who had
received a vaccine, fewer than half had received all 3 doses
recommended by the CDC18; this deficiency varied widely
among the sites and was especially high in the Andes.
In contrast to low vaccination rates before the trial,
vaccine uptake during the trial was excellent with over 97%
of eligible participants receiving at least 1 dose and 85%
receiving the complete series; the vaccine response rate (as
reflected by HBsAb seroconversion) for those completing the
series was 87%, consistent with the CDC data regarding
vaccine immunogenicity.19 The acute HBV infections that
occurred during the study highlight how prevention through
vaccination is imperative, and the low rates of global
vaccination provide a clear opportunity for disease prevention.
Engaging adult MSM and transgender women in PrEP
programs may offer a unique opportunity to increase vacci-
nation rates. Interestingly, there is also some evidence from
a recent retrospective study that use of hepatitis B-active
antiretroviral therapy for treatment of HIV (lamivudine,
emtricitabine, and TFV) led to a lower incidence of hepatitis
B acquisition than the use of antiretrovirals without hepatitis B
activity.20 This effect was especially apparent when TFV was
used, which provides another protective benefit of FTC/TDF
use and is consistent with our data, showing that no acute
HBV infections occurred after 4 weeks on FTC/TDF; both
cases of acute HBV infection that occurred in the placebo arm
occurred later. These findings suggest that FTC/TDF might
serve to prevent hepatitis B-susceptible people from acquiring
hepatitis B before completion of the vaccine series.
Among the 12 participants enrolled in the study with
chronic hepatitis B, almost all of those tested had no evidence
of antiviral drug resistance (8/9). One isolate from a participant
randomized to the placebo arm showed possible resistance to
lamivudine and telbivudine. No participant had virus associ-
ated with resistance mutations against TFV, and no partic-
ipants experienced a flare either during the trial or after drug
discontinuation, although one participant whose LFTs were
normal while on study drug developed a low-grade, asymp-
tomatic, and self-limited elevation of the transaminases after
PrEP discontinuation. The majority with chronic hepatitis B
randomized to FTC/TDF (5 of 6) had visits when drug was
detected followed by visits when no drug was detected,
indicating inconsistent adherence, and yet, none experienced
a hepatitis B flare. It is possible that flares were absent because
individuals with evidence of liver dysfunction were excluded.
The risk of flares with FTC discontinuation seems to be
limited to people with advanced liver disease.21
Interestingly, TFV use in chronic hepatitis B in the setting
of cirrhosis has led to regression of fibrosis.22 Regarding the 2
cases of acute HBV infection within the FTC/TDF arm, 1
resolved with development of immunity and the other resolved
clinically with loss of circulating antigen but remained HBsAb
negative. It is not known whether this person may have
a recurrence of HBV antigenemia after stopping PrEP.
The principal limitation of this study is the small number
of enrolled participants with active HBV infection, which limits
the ability to provide definitive conclusions regarding the safety
of PrEP use in the context of HBV infection in MSM/TGW or
conclusive guidance related to best practices. Our results are
reassuring, however, in that none of the participants in iPrEx
with chronic HBV infection developed a flare during intermittent
use of PrEP and even after drug discontinuation.
We agree with the CDC that screening for HBsAg
should occur before PrEP initiation; while most providers
prescribing PrEP are compliant with most PrEP guidelines,
only approximately 60% of providers are screening for HBV
infection.23 Obtaining HBsAg alone followed by HBV DNA
(when available) for individuals with a positive HBsAg may
be the only required testing before initiating PrEP, especially
in resource-limited settings in which obtaining additional
serologies may be more expensive than vaccination.
We did not find that testing for HBsAb, HBcAb,
HBcAb IgM, HBeAb, or HBeAg added value for the
purposes of assessing PrEP eligibility. Importantly, persons
with isolated HBcAb (and negative HBsAg and HBsAb) were
all HBV DNA negative with normal LFTs, indicating that this
common pattern of serologies was consistent immunity from
FIGURE 2. A, Cases of chronic hepatitis B infection randomized to FTC/TDF. B, Cases of acute hepatitis B infection randomized to
FTC/TDF.
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prior infection rather than active infection with a HBV
mutant. Individuals with HBV infection who are interested
in PrEP can be safely started on FTC/TDF, which will also
provide excellent activity against HBV24; consistent adher-
ence may be required to prevent development of resistance.
This experience, combined with prior evidence showing
no hepatitis flares among 23 women during and after oral TDF
PrEP,12 demonstrates that PrEP can often be safely started and
stopped in persons with HBV infection who do not have
cirrhosis or transaminase elevations at PrEP initiation. As
information is limited and treatment for HBV infection is
complex, referral to a specialist is appropriate when available,
especially for PrEP discontinuation. At that time, a separate
decision regarding continuing FTC/TDF or switching manage-
ment strategies for HBV infection must be reached.5 Such
a decision would be based on further testing to evaluate cirrhosis
to determine the need for ongoing hepatitis B treatment.25,26
Individuals infected with HBV should have monitoring
of LFTs (and possibly HBV viral load where available) every
6–12 months while on PrEP to ensure that the emergence of
HBV resistance to FTC/TDF has not occurred, a theoretical
concern with suboptimal adherence.5 Although TDF presents
a high barrier to developing HBV drug resistance, especially
when given as combination therapy,27 inconsistent adherence
due to intermittent dosing may lead to drug resistance,28 yet
no cases have been reported. We did not observe any TDF
resistance during the iPrEx study during which adherence to
the daily regimen occurred in a minority of participants.2
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